Last updated: June 1, 2026
ALLEGRA Allergy (fexofenadine) Supplier Landscape: API, Finished Dosage, Toll Manufacturing, and Packaging Options
Executive summary: Allegra Allergy is fexofenadine (HCl) in U.S. branded and generic forms across tablets and oral suspension. The supplier base spans: (1) API manufacturers for fexofenadine HCl, (2) contract manufacturing organizations (CMOs) that produce solid oral dosage and liquid suspension, and (3) packaging and fill-finish suppliers for unit-dose and retail bottle formats. Public information on exact “brand Allegra” supplier-of-records changes by product and fiscal year, but the market is structurally concentrated around global generic/API producers and mid-tier CMOs that support NDA/ANDA filing and lifecycle manufacturing.
Who supplies the Allegra Allergy drug products (fexofenadine) in the US market?
Finished-dose supply for Allegra is handled by the brand manufacturer(s) for branded products and by ANDA holders for generics, with downstream outsourcing to CMOs and packaging vendors. Allegra is not a single-source product. In practice, the supply chain breaks into: API source, dosage form manufacturing, and secondary packaging.
What dosage forms are commonly supplied for fexofenadine (Allegra Allergy)?
- Oral tablets (strengths vary by market; U.S. includes 30 mg and 60 mg formulations historically, and 180 mg once-daily branded/generic)
- Oral suspension (when marketed in pediatric dosing formats; composition and particle specs differ by product)
- Combination and comparator SKUs in the market are usually separate ANDA/NDA products and have distinct manufacturing/packaging sources
What suppliers provide the fexofenadine (API) used for Allegra Allergy?
Fexofenadine API is sold globally by specialty and generic API producers. For Allegra-branded and generic products, manufacturers source API either from in-house production or external API suppliers under commercial agreements and quality agreements (GMP, CoA, impurity profiles, polymorph control, and stability).
Which API supplier types dominate the fexofenadine market?
- Specialty chemical API producers that run multi-step routes to fexofenadine HCl and control crystal form and residual solvent specs
- Generic API producers that supply standardized intermediates and final API to ANDA makers
- China and India-based API networks that often supply international ANDA holders and CMOs under multiple quality systems and site approvals
How do API specs affect CMO selection for Allegra Allergy formulations?
CMOs typically require:
- Confirmed impurity profile and limits matching the finished product filing
- Consistent particle size and polymorph/crystal form for bioavailability equivalence (especially for suspension and fast-dissolve tablet performance)
- Stability data across relevant temperature/humidity conditions
Which contract manufacturers (CMOs) produce fexofenadine tablets and oral suspension?
CMOs supplying fexofenadine typically cover:
- Solid oral dose manufacturing: blend, granulation, tablet compression or direct compression, coating, and line clearance validation
- Liquid suspension manufacturing: dispersion preparation, viscosity control, preservative/system selection, container closure integrity, and fill-finish
What CMO capabilities are required for Allegra Allergy oral suspension?
Oral suspension production is sensitive to:
- Uniform distribution of API in suspension (settle-out control)
- Rheology targets for resuspendability
- Microbial control and preservative system alignment
- Stability across “shake well” use patterns
What packaging suppliers support Allegra Allergy retail formats?
Packaging suppliers include:
- Bottling and unit-dose packaging vendors for retail pharmacies
- Serialization and track-and-trace service providers where required
- Labeling and compliance printing partners (NDC, lot, expiration, UDI where applicable)
Which packaging configurations are most common for fexofenadine products?
- HDPE bottles with induction seals and child-resistant closures
- Blister packs for tablet SKUs where adopted by specific ANDA/labeling strategies
- Carton and blister labeling systems that integrate pharmacy-ready labeling formats
How many supplier sites typically support fexofenadine products in the US?
The market usually has multiple qualified manufacturing sites:
- API: multiple global sites for commercial supply
- Finished-dose manufacturing: multiple ANDA/labeler sites plus CMOs under tech transfer
- Packaging: at least one primary packaging vendor per packaging configuration and lot control strategy
This multi-site structure is standard for stability of supply and to manage batch production schedules around regulatory release testing and market demand.
What patent and regulatory constraints shape supplier eligibility for Allegra Allergy?
Supplier eligibility is driven by regulatory approvals and product sameness requirements.
What FDA regulatory status controls generic and CMO manufacturing for fexofenadine?
- ANDA products must demonstrate sameness in active ingredient (fexofenadine HCl), strength, dosage form, route of administration
- Suspensions require strict bioequivalence approaches consistent with FDA standards for liquid products
- Facilities must be registered and comply with GMP expectations for the dosage form class
What data packages do suppliers need to support transfers to a new site?
- Comparative dissolution and performance data (especially for solid oral dose)
- Process validation evidence for blend uniformity, coating uniformity, and dissolution specs
- Stability and compatibility data for suspension container closure systems
Who are the key branded and generic companies sourcing or supplying fexofenadine for Allegra Allergy?
The “supplier” in market terms can mean the NDA/ANDA labeler (marketing authorization holder). Branded Allegra is historically associated with Sanofi for U.S. operations, while many generic versions are marketed by multiple labelers. Labelers typically rely on their own manufacturing or qualified CMOs.
How do branded and generic supply chains differ?
- Branded: tighter internal control with fewer site changes unless contract manufacturing is used
- Generic: more frequent multi-site and tech-transfer moves tied to ANDA strategy and lifecycle economics
What generic entry risks affect future fexofenadine supplier availability?
The supplier ecosystem can tighten if:
- High-cost impurity control limits reduce qualified API sources
- Liquid suspension manufacturing capacity is constrained
- Market demand spikes for a specific SKU and forces line prioritization
Supply risk is primarily a manufacturing capacity and regulatory compliance issue rather than a single-source dependence, because multiple ANDA products usually compete on the same active ingredient.
How does ALLEGRA Allergy compare with other fexofenadine brands and generics on supply readiness?
All products containing fexofenadine share the same active ingredient, so the dominant differentiators are:
- Dosage form and excipient system
- Bioequivalence and performance
- Manufacturing site qualification and release testing throughput
What does this imply for procurement decisions?
Procurement teams should evaluate:
- Manufacturing-site track record (FDA inspection outcomes, recall history if any)
- Batch release timelines
- Packaging format and lead times
What should procurement teams look for when selecting suppliers for Allegra Allergy (fexofenadine)?
Key procurement due diligence focuses on:
1) API provenance and quality agreement
- CoA coverage, impurity profile match, and lot-to-lot consistency
- GMP certificate status for API site
- Residual solvent and heavy metals compliance
2) Finished-dose CMO capabilities
- Prior experience with fexofenadine tablets and/or oral suspension
- Documented control strategy for dissolution and dispersion uniformity
- Release testing capacity and method validation
3) Packaging supplier compliance
- Child-resistant closure validation for bottle formats
- Induction seal performance
- Serialization integration where required
Key takeaways
- Allegra Allergy is supplied through a multi-tier chain: fexofenadine HCl API sites, finished-dose manufacturers (often via CMOs), and packaging/fill-finish vendors.
- Supplier qualification is mainly governed by FDA GMP compliance, ANDA/NDA product sameness requirements, and performance specs (dissolution for tablets, dispersion and resuspendability for suspensions).
- Procurement and licensing diligence should prioritize qualified manufacturing sites, API impurity controls, fill-finish compatibility, and packaging compliance lead times.
FAQs
- What excipient and suspension formulation factors most affect fexofenadine oral suspension performance?
- How do API impurity profiles for fexofenadine HCl affect ANDA batch acceptance by release testing?
- What manufacturing controls are critical for ensuring uniform blend content in fexofenadine tablets?
- Do packaging changes (bottle vs blister) require regulatory bridging for fexofenadine products?
- What supply constraints are most common for liquid antihistamine suspensions like fexofenadine?
References
- FDA. “ANDA (Abbreviated New Drug Application).” U.S. Food and Drug Administration.
- FDA. “Oral Dosage Forms: Waiver of In Vivo Bioavailability and Bioequivalence Studies.” U.S. Food and Drug Administration.
- FDA. “Current Good Manufacturing Practice for Finished Pharmaceuticals.” U.S. Food and Drug Administration.
